Breast Cancer

T-DXd demonstrated improved and durable response rates in heavily pretreated patients with advanced HER2-positive breast cancer.

The addition of pertuzumab to the previous standard of trastuzumab plus chemotherapy as an adjuvant therapy for patients with operable HER2-positive early breast cancer continued to reduce the risk for recurrence and death during a 6-year updated analysis.

Adjuvant therapy with S-1, an oral fluoropyrimidine-based drug, plus endocrine therapy postoperatively significantly increased invasive disease-free survival (IDFS) in patients with HR-positive, HER2-negative breast cancer.

The Food and Drug Administration approved the first generic for everolimus, which can provide a safe, effective, lower cost alternative to the brand-name drug it references.

Nancy Davidson, MD, from Seattle Cancer Care Alliance and Fred Hutchinson Research Center, discussed advancements in breast cancer.

Research suggests that there is an association between breast cancer risk and the use of chemical straighteners and permanent hair dyes.

The FDA approved FoundationOne CDx as a companion diagnostic for alpelisib in combination with fulvestrant for the treatment of men and postmenopausal women with HR+/HER2- PIK3CA-mutated breast cancer.

Patients who previously received radiotherapy for ductal carcinoma in situ may have higher mortality after developing an invasive second breast cancer.

The breast cancer expert discussed the importance of attending breast cancer meetings like the San Antonio Breast Cancer Symposium and the Miami Breast Cancer Conference.

Patients with endometrial cancer pose a very high risk of dying from cardiovascular diseases in the year after diagnosis, suggesting the necessity of early involvement of cardiologists for these patients.

Henlius announced that their multicenter phase III study met its primary end point of best overall response rate at week 24.

Oncotype DX® Breast Recurrence Scores from the National Cancer Database indicated that a lower threshold is needed for male patients with early stage ER-positive breast cancer to predict mortality.

Fergus Couch, PhD, from the Mayo Clinic, discusses with CancerNetwork about the new research with the CARRIERS study for African American patients with breast cancer.

A quality improvement study indicated that nudges in the electronic health record were associated with a significant increase in clinician ordering of screening tests for breast and colorectal cancer.

The US Food and Drug Administration recently approved alpelisib plus fulvestrant for the treatment of metastatic or otherwise advanced breast cancer.

Highlights of breast cancer advances at the ESMO Congress.

Jason Williams, MD, discusses the development of intratumoral immunotherapy, as well as trial results from his poster presentation at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).

Biosimilars have shown to be cost-effective treatments in oncology and hematology, according to Jacopo Giuliani, MD.

MCLA-128 showed radiological and clinical responses in patients with certain types of cancer who harbored neuregulin 1 gene fusions.

Treatment with trastuzumab emtansine demonstrated similar overall survival across 3 treatment arms of patients with HER2‐positive metastatic breast cancer.

A blood test which may detect the traces of developing breast cancer through autoantibodies years before clinical signs show themselves is now proposed by researchers in the United Kingdom.

Dr. Allison W. Kurian discusses a new breast cancer study that analyzed the mutations present in breast tumors, and about emerging targeted therapy options.

A new study examined differences in breast cancer recurrence and survival by region.

High testosterone and low folate intake together may drastically increase risk of breast cancer.

Patients, providers, and healthcare processes benefit from systematically collecting patient-reported outcomes and reviews of their experiences in breast cancer treatment.

Two trials and 3000 patients with HER2-positive breast cancer were analyzed for recurrence risk 5 to 10 years after diagnosis.

Tucatinib showed improvements in survival in patients with HER2-positive breast cancer.

The results of this new study could also further explain the patterns of tumor development among certain ethnicities.

Radiologists and data scientists decided to get together to evaluate the effectiveness of artificial intelligence and human observation when it comes to detecting breast cancer in mammograms.

For the first time, researchers have isolated a subtype of gamma-delta T-cells that offers protection in women with triple-negative breast cancer.